TrialsgrambêtaRCTs are beautiful
ESC Congress 2026Présenté sam. 29 août · 08:30 UTC+2Hot Line 2Tous les essais Hot Line →

AMUNDSEN

2026

Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world

In 2,161 patients with acute myocardial infarction undergoing PCI, evolocumab started before PCI increased achievement of an LDL-C reduction of ≥50 % to below 1.4 mmol/L at 12 months compared with standard lipid-lowering care.

Résultat

Efficacité: Achievement of both a ≥50% LDL-C reduction from baseline and LDL-C <1.4 mmol/L (55 mg/dL) at 12 months; main clinical endpoint the composite of all-cause death or unplanned cardiovascular hospitalisation at 12 monthsadjusted OR 5,54 (IC à 95 % 4,50-6,82) · P < 0,001

En dessous de 1 en faveur de standard lipid-lowering care, au-dessus de 1 en faveur de evolocumab started before PCI.

Taux d’événements
Différence absolue
42,0 points
NNT
3

La différence absolue et le NNT sont dérivés des taux d’événements.

Également rapporté: Primary lipid endpoint met: median LDL-C at 6 weeks 16 vs 56 mg/dL. No clinical benefit: death or unplanned cardiovascular hospitalisation at 12 months 159/1087 (14.6%) vs 165/1074 (15.4%), adjusted OR 0.94 (95% CI 0.73–1.19), p=0.59

Publication originale
Sous-thème
PCSK9 inhibition in ACS
Schéma
International, investigator-initiated Phase IV PROBE RCT, 1:1, first evolocumab dose given before PCI, 12-month primary follow-up (clinical follow-up continuing to 2028)
Pertinence
Important: l’un des piliers parmi d’autres.
Source
Montalescot G, Ferrari E, Souteyrand G, et al. JAMA. 2026; published online 29 August.doi 10.1001/jama.2026.17302

Discussion et critique

Giving the PCSK9 antibody before the wire crosses does what the pharmacology promises: four in five reach the guideline target at a year against two in five, with a median LDL-C of 16 mg/dL at six weeks. What it does not do, over twelve months, is change death or cardiovascular readmission: an open-label trial powered for a laboratory endpoint, not for events. The lipid result is the argument for starting early; the clinical arm is the reminder that a year is short for a curve that separates late.

Discuté dans des podcasts